Home/ Stocks/ ORKA

Oruka Therapeutics, Inc. Common Stock

ORKA XNAS

$92.20 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$6.10B

About Oruka Therapeutics, Inc. Common Stock

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 68 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-41,206,000	N/A
Q1 2026	$0	$-31,820,000	N/A
FY 2025	$0	$-105,433,000	N/A
Q3 2025	$0	$-30,277,000	N/A

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 10, 2026

Calendar →

Related Market News

No specific coverage for ORKA yet. Check out our latest market news or earnings calendar.

Get ORKA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Oruka Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.